These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 26895767)

  • 21. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
    Dziuba J; Alperin P; Racketa J; Iloeje U; Goswami D; Hardy E; Perlstein I; Grossman HL; Cohen M
    Diabetes Obes Metab; 2014 Jul; 16(7):628-35. PubMed ID: 24443793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.
    Shao SC; Chang KC; Hung MJ; Yang NI; Chan YY; Chen HY; Kao Yang YH; Lai EC
    Cardiovasc Diabetol; 2019 Sep; 18(1):120. PubMed ID: 31551068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
    Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
    Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
    Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
    Avogaro A; Giaccari A; Fioretto P; Genovese S; Purrello F; Giorgino F; Del Prato S
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):763-772. PubMed ID: 28431476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.
    Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
    Diabetes Obes Metab; 2017 Jun; 19(6):831-841. PubMed ID: 28116795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
    Petrie MC; Verma S; Docherty KF; Inzucchi SE; Anand I; Belohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett J; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Vinh PN; Schou M; Tereshchenko S; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Johanson P; Greasley PJ; Boulton D; Bengtsson O; Jhund PS; McMurray JJV
    JAMA; 2020 Apr; 323(14):1353-1368. PubMed ID: 32219386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.
    Johnsson KM; Ptaszynska A; Schmitz B; Sugg J; Parikh SJ; List JF
    J Diabetes Complications; 2013; 27(5):479-84. PubMed ID: 23806570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
    Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
    Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
    J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
    McMurray JJV; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Anand IS; Bělohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett JG; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Petrie MC; Vinh PN; Schou M; Tereshchenko S; Verma S; Held C; DeMets DL; Docherty KF; Jhund PS; Bengtsson O; Sjöstrand M; Langkilde AM;
    N Engl J Med; 2019 Nov; 381(21):1995-2008. PubMed ID: 31535829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC; Borghi C; Consoli A; Volpe M
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
    Lundkvist P; Pereira MJ; Katsogiannos P; Sjöström CD; Johnsson E; Eriksson JW
    Diabetes Obes Metab; 2017 Sep; 19(9):1276-1288. PubMed ID: 28345814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
    Leiter LA; Cefalu WT; de Bruin TW; Xu J; Parikh S; Johnsson E; Gause-Nilsson I
    Diabetes Obes Metab; 2016 Aug; 18(8):766-74. PubMed ID: 27009868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes.
    Al-Bazz DY; Wilding JP
    Future Cardiol; 2020 Mar; 16(2):77-88. PubMed ID: 31914812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dapagliflozin: a review of its use in type 2 diabetes mellitus.
    Plosker GL
    Drugs; 2012 Dec; 72(17):2289-312. PubMed ID: 23170914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.